Are pyridazines privileged structures?

MedChemComm

Volumn 2, Issue 10, 2011, Pages 935-941

  Wermuth, Camille G ^a  

^a Prestwick Chemical Inc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 DIETHYLAMINO 2 METHYLPROPYLAMINO) 6 PHENYL 5 PROPYLPYRIDAZINE; 3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; 3 METHOXY 6 [4 (3 METHYLPHENYL) 1 PIPERAZINYL]PYRIDAZINE; ATRIMYCIN; AZAMERONE; BAZINAPRINE; CIRRATIOMYCIN A; CISPLATIN; CM 30038; CM 30094; DIAZEPAM; ENDIXAPRINE; HETEROCYCLIC COMPOUND; HYDRALAZINE; L 365209; METHYLETHYLPYRIDAZONE; MINAPRINE; MOXIRAPRINE; PCS 1055; PLATINUM COMPLEX; PYRAZOLOPYRIMIDOPYRIDAZINONE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIDAZOMYCIN; SULFAMETHOXYPYRIDAZINE; SULPIRIDE; THIENOPYRIDAZINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; AQUEOUS SOLUTION; CRYSTAL STRUCTURE; CYCLIZATION; DEHYDROGENATION; DRUG DESIGN; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; LACTOBACILLUS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACOPHORE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SOLUBILITY; STREPTOCOCCUS; STREPTOMYCES; STREPTOMYCES CIRRATUS; STREPTOMYCES SILVENSIS; STREPTOMYCES VIOLACEUSNIGER; STREPTOMYCES XANTHOCIDICUS;

EID: 80053601542     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c1md00074h     Document Type: Review

References (26)

1. C. G. Wermuth Etude de la condensation de l'acide pyruvique avec les aldéhydes aliphatiques non substitutes en α. I.- Produits de condensation dont la chaîne carbonée est ramifiée: semialdéhydes méthyl-alcoyl maliques et semialdéhydes méthyl-alcoyl maléiques Bull. Soc. Chim. Fr. 1965 2242 2249
2. C. G. Wermuth Etude de la condensation de l'acide pyruvique avec les aldéhydes aliphatiques non substitutes en α. II.- Produits de condensation dont la chaîne carbonée est linéaire: acides α-cétoniques β γ-éthyléniques et α-céto γ-butyrolactones Bull. Soc. Chim. Fr. 1966 1435 1444
3. H. Laborit C. G. Wermuth F. Leterrier C. Baron La méthyl-4 éthyl-5 pyridazone (MEP) (Ag 147) Agressologie 1965 6 401 410
4. G. Heinisch and H. Frank, Pharmacologically Active Pyridazines. Part 1, in Progress in Medicinal Chemistry, ed., G. P. Ellis, and, G. B. West, Elsevier, Amsterdam, 1990, vol. 27, pp. 1-49
5. G. Heinisch and H. Kopelenk-Frank, Pharmacologically Active Pyridazines. Part 2, in Progress in Medicinal Chemistry, ed., G. P. Ellis, and, D. K. Luscombe, Elsevier, Amsterdam, 1992, vol. 29, pp. 141-183
6. R. Grote Y. Chen A. Zeeck Metabolic products of microorganisms 243. Pyridazomycin, a new antifungal antibiotic produced by Streptomyces violaceoniger J. Antibiot. 1988 41 595 601
7. H. Bockholt J. M. Beale J. Rohr Biosynthesestudien an pyridazomycin Angew. Chem., Int. Ed. Engl. 1994 33 1648 1651
8. J. M. Winter A. L. Jansma T. M. Handel B. S. Moore Formation of the pyridazine natural product azamerone by biosynthetic rearrangement of an aryl diazoketone Angew. Chem., Int. Ed. 2009 48 767 770
9. Y. Nakamura A. Ito C. Shin Dehydrooligopeptides. XVI. convenient syntheses of two kinds of antrimycins Av and Dv containing dehydrovaline residues Bull. Chem. Soc. Jpn. 1994 67 2151 2161 (Pubitemid 24315401)
10. P. Hughes J. Clardy Total synthesis of 3(S)-carboxy-4(S)-hydroxy-2,3,4,5- tetrahydropyridazine, an unusual amino acid constituent of luzopeptin A J. Org. Chem. 1989 54 3260 3264
11. D. J. Pettibone B. V. Clineschmidt P. S. Anderson R. M. Freidinger G. F. Lundell L. R. Koupal C. D. Schwartz J. M. Williamson M. A. Goetz O. D. Hensens J. M. Liesch J. P. Springer A structurally unique, potent, and selective oxytocin antagonist derived from Streptomyces silvensis Endocrinology 1989 125 117 122
12. W. Schneider The dipole moments of diazines J. Am. Chem. Soc. 1948 70 627 630
13. M. S. Chapman I. Minor M. G. Rossmann G. D. Diana K. Andries Human rhinovirus 14 complexed with antiviral compound R 61837 J. Mol. Biol. 1991 217 455 463 (Pubitemid 121003293)
14. S. Komeda G. V. Kalayda M. Lutz A. L. Spek Y. Yamanaka T. Sato M. Chikuma J. Reedijk New isomeric azine-bridged dinuclear platinum(ii) complexes circumvent cross-resistance to cisplatin J. Med. Chem. 2003 46 1210 1219 (Pubitemid 36428226)
15. R. J. Gleave P. J. Beswick A. J. Brown G. M. P. Giblin P. Goldsmith C. P. Haslam W. L. Mitchell N. H. Nicholson L. W. Page S. Patel S. Roomans B. P. Slingsby M. E. Swarbrick Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB2 agonists for the treatment of inflammatory pain Bioorg. Med. Chem. Lett. 2010 20 465 468
16. G. Heinisch W. Holzer F. Kuntz T. Langer P. Lukavski P. Pechlaner H. Weissenberger On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor ridogrel J. Med. Chem. 1996 39 4058 4064 (Pubitemid 26327442)
17. D. Rognan P. Sokokoff A. Mann M.-P. Martres J.-C. Schwartz J. Costentin C. G. Wermuth Optically active benzamides as predictive tools for mapping the dopamine D2 receptor Eur. J. Pharmacol. 1990 189 59 70 (Pubitemid 20252997)
18. C. G. Wermuth K. Bizière Pyridazinyl-GABA derivatives: a new class of synthetic GABA-A antagonists Trends Pharmacol. Sci. 1986 7 421 424
19. C. G. Wermuth J.-J. Bourguignon G. Schlewer J.-P. Gies A. Schoenfelder A. Melikian M.-J. Bouchet D. Chantreux J.-C. Molimard M. J.-P. C. Heaulme K. Bizière Synthesis and structure-activity relationships of a series of aminopyridazine derivatives of gamma-aminobutyric acid acting as selective GABA-A antagonists J. Med. Chem. 1987 30 239 249 (Pubitemid 17003793)
20. C. Hamdouchi C. Sanchez-Martinez J. Gruber M. del Prado J. Lopez A. Rubio B. A. Heinz Imidazo[1,2-b]pyridazines, novel nucleus with potent and broad spectrum activity against human picornaviruses: design, synthesis and biological evaluation J. Med. Chem. 2003 46 4333 4341 (Pubitemid 37157998)
21. B. M. Fox K. Iio K. Li R. Choi I. Takashi S. Jackson S. Sagawa B. Shan M. Tanaka A. Yoshida F. Kayser Discovery of pyrrolopyridazines as novel DGAT 1 inhibitors Bioorg. Med. Chem. Lett. 2010 20 6030 6033
22. B. Dyck S. Markison L. Zhao J. Tamiya J. Grey M. W. Rowbottom M. Zhang T. Vickers K. Sorensen C. Norton J. Wen C. E. Heise J. Saunders P. Conlon A. Madan D. Schwarz V. S. Goodfellow A thienopyridazinone-based melanin-concentrating hormone receptor 1 antagonist with potent in vivo anorectic properties J. Med. Chem. 2006 49 3753 3756 (Pubitemid 43967871)
23. M. P. Giovannoni C. Vergelli C. Biancalani N. Cesari A. Graziano P. Biagini J. Gracia A. Gavalda V. Dal Paz Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction J. Med. Chem. 2006 49 5363 5371 (Pubitemid 44260230)
24. B. E. Evans, K. E. Rittle, M. G. Bock, R. M. DiPardo, R. M. Freidinger, W. L. Whitter, G. F. Lundell, D. F. Veber, P. S. Anderson, R. S. L. Chang, V. J. Lotti, D. J. Cerino, T. B. P. J. K. Chen, K. A. Kunkel, J. P. Springer and J. Hirshfield, Methods for Drug Discovery: Development of Potent, Selective, Orally Effective Cholecystokinin Antagonists, J. Med. Chem., 1988, 31, 2235 2246 (Pubitemid 19001640)
25. K. Russell and W. F. Michne, The Value of Chemical Genetics in Drug Discovery, in Chemogenomics in Drug Discovery, ed., H. Kubinyi, and, G. Müller, VCH, 2004, pp. 69-96
26. A. Kolinsky, Lead-Likeness and Drug-Likeness, in The Practice of Medicinal Chemistry, ed., C. G. Wermuth, Elsevier, San Diego, 2008, pp. 244-254